186 related articles for article (PubMed ID: 32037846)
21. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
22. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Starenki D; Hong SK; Wu PK; Park JI
Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
[TBL] [Abstract][Full Text] [Related]
23. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract][Full Text] [Related]
24. Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.
S Temperley T; Temperley HC; O'Sullivan NJ; Corr A; Brennan I; Kelly ME; Prior L
Ir J Med Sci; 2024 Jun; 193(3):1143-1147. PubMed ID: 37922099
[TBL] [Abstract][Full Text] [Related]
25. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
26. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
[TBL] [Abstract][Full Text] [Related]
27. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.
Blevins DP; Dadu R; Hu M; Baik C; Balachandran D; Ross W; Gunn B; Cabanillas ME
Thyroid; 2014 May; 24(5):918-22. PubMed ID: 24635127
[TBL] [Abstract][Full Text] [Related]
28. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
[TBL] [Abstract][Full Text] [Related]
29. Novel therapies for thyroid cancer.
Krajewska J; Jarzab B
Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
[TBL] [Abstract][Full Text] [Related]
30. Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Rajabi S; Hedayati M
Mol Diagn Ther; 2017 Dec; 21(6):607-620. PubMed ID: 28698976
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
Markowitz JN; Fancher KM
Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
[TBL] [Abstract][Full Text] [Related]
32. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
34. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
35. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
37. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
[TBL] [Abstract][Full Text] [Related]
39. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
[TBL] [Abstract][Full Text] [Related]
40. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
